|
Revlimid
Hi Neil,
Yes, and the important issues in Jäderlunds thesis is that the researchers are trying to make a pre-treatment risk-stratification.
We already know much about which patients that will respond to EPO like Aranesp and drugs like Neupogen (these findings are not new):
1 Patients with a transfusion need less than 2 units of packed red blood cells a month.
2 Patients with a Serum-EPO less than 500 U/l
A patient that have both these variables will respond in 74 % of the cases, a patient with one of these variables in 23 % of the cases and patients without these variables in 7 % of the cases.
Then we hope that the researchers will be able to assess the expression of individual genes especially the SPARC gene expression in all patients. If the SPARC expression levels are increased by Revlimid the patients will respond to the treatment.
Kind regards
Birgitta-A
|